Two-year efficacy and safety update from the phase III CheckMate 025 study of nivolumab versus everolimus in patients with advanced renal cell carcinoma (aRCC) Meeting Abstract
| Authors: | Plimack, E. R.; Motzer, R. J.; Escudier, B.; Sharma, P.; McDermott, D. F.; George, S.; Hammers, H. J.; Carducci, M.; Tykodi, S. S.; Sosman, J. A.; Choueiri, T. K.; Donskov, F.; Gurney, H.; Gauler, T. C.; Ueda, T.; Zhao, H. Y.; Berghorn, E.; Wagstaff, J. |
| Abstract Title: | Two-year efficacy and safety update from the phase III CheckMate 025 study of nivolumab versus everolimus in patients with advanced renal cell carcinoma (aRCC) |
| Meeting Title: | 15th International Kidney Cancer Symposium |
| Journal Title: | BJU International |
| Volume: | 118 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2016 Nov 4-5 |
| Meeting Location: | Miami, FL |
| ISSN: | 1464-4096 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2016-12-01 |
| Start Page: | 11 |
| End Page: | 12 |
| Language: | English |
| ACCESSION: | WOS:000388478200016 |
| PROVIDER: | wos |
| PUBMED: | 27860174 |
| DOI: | 10.1111/bju.13694 |
| Notes: | Meeting Abstract -- Source: Wos |
